Form 4 · Filed Jun 11, 2026, 08:41 PM UTC
KALV/KalVista Pharmaceuticals, Inc.
Stuart Nancy — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
5 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | D | other | 14,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 10,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 10,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 10,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 30,000 | — | — | 0 |
Source: SEC EDGAR raw filing ↗ · Accession 0001594774-26-000002